GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Myomo Inc (AMEX:MYO) » Definitions » Debt-to-EBITDA

Myomo (MYO) Debt-to-EBITDA : -0.06 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Myomo Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Myomo's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.49 Mil. Myomo's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.12 Mil. Myomo's annualized EBITDA for the quarter that ended in Dec. 2023 was $-9.41 Mil. Myomo's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.06.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Myomo's Debt-to-EBITDA or its related term are showing as below:

MYO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.67   Med: -0.08   Max: -0.02
Current: -0.08

During the past 8 years, the highest Debt-to-EBITDA Ratio of Myomo was -0.02. The lowest was -1.67. And the median was -0.08.

MYO's Debt-to-EBITDA is ranked worse than
100% of 432 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs MYO: -0.08

Myomo Debt-to-EBITDA Historical Data

The historical data trend for Myomo's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myomo Debt-to-EBITDA Chart

Myomo Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial -0.25 -0.02 -0.07 -0.06 -0.08

Myomo Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.04 -0.09 -0.09 -0.06

Competitive Comparison of Myomo's Debt-to-EBITDA

For the Medical Devices subindustry, Myomo's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myomo's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Myomo's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Myomo's Debt-to-EBITDA falls into.



Myomo Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Myomo's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.486 + 0.115) / -7.714
=-0.08

Myomo's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.486 + 0.115) / -9.412
=-0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Myomo  (AMEX:MYO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Myomo Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Myomo's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Myomo (MYO) Business Description

Traded in Other Exchanges
Address
137 Portland Street, 4th Floor, Boston, MA, USA, 02114
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The Company provides the device to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The Company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
Executives
Thomas F Kirk director
Milton Mayo Morris director 2121 ALLEN PARKWAY, APT 4075, HOUSTON TX 77019
Paul R Gudonis director, officer: Chief Executive Officer 9 HICKORY ROAD, MANCHESTER MA 01944
David A Henry officer: Chief Financial Officer
Harry Kovelman officer: Chief Medical Officer C/O MYOMO, INC., 137 PORTLAND ST., 4TH FLOOR, BOSTON MA 02114
Yitzchak Jacobovitz director MYOMO, INC., 137 PORTLAND ST., 4TH FLOOR, BOSTON MA 02114
Micah Mitchell officer: Chief Commercial Officer C/O MYOMO, INC., ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA 02139
Crowley Thomas Aloysius Jr. director 19 ST CLAIR AV, SPRING LAKE NJ 07762
Cliff Conneighton officer: Chief Marketing Officer 53 DEPOT ROAD, HOLLS NH 03049
Jonathan Naft officer: VP, General Manager C/O MYOMO, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Brandon M Green officer: Chief Medical Officer C/O MYOMO, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ralph A Goldwasser officer: Chief Financial Officer BNN CORP, 150 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Davie Mendelsohn officer: VP, Sales C/O MYOMO, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Steve Sanghi director 2355 W CHANDLER BLVD, CHANDLER AZ 85224-6199
Amy K. Knapp director 75 N. MOUNTAIN AVE, MONTCLAIR NJ 07042